Skip to main content
Erschienen in: PharmacoEconomics 11/2008

01.11.2008 | Review Article

The Impact of Influenza on Working Days Lost

A Review of the Literature

verfasst von: Dr Martin Keech, Paul Beardsworth

Erschienen in: PharmacoEconomics | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Seasonal influenza is a prevalent and highly contagious acute respiratory disease that, year on year, results in increased morbidity and mortality on a global scale. Because of the widespread and debilitating nature of the disease, annual influenza epidemics result in substantial workplace absenteeism, and the associated cost of lost productivity is a significant component of the substantial financial burden of the disease to society. The objective of this review was to identify studies that had attempted to quantify the impact of influenza upon otherwise healthy adults in terms of working days lost associated with an episode of influenza.
Studies were included if they reported estimates of working days lost due to clinical, physician and/or self-diagnosis in adult patients or their dependants, or where this figure could be estimated from the data. Searches were conducted in MEDLINE, EMBASE, BIOSIS and the Cochrane Collaboration for articles published since 1995 in English, French or German. Of the 289 papers identified in the search, 28 (9.7%) met the inclusion criteria. The studies, involving study sites in North America, Western Europe, Asia and Australia, were categorized into three groups: (i) those reporting influenza diagnoses confirmed by laboratory testing, i.e. studies where influenza was the unambiguous cause of the working days lost (n = 7 studies reported in ten publications); (ii) those where influenza was confirmed by a physician without an accompanying laboratory test (n = 4 studies); and (iii) those where influenza was self-reported by study participants (n = 14 studies). Qualitative reporting of results was performed because of the large degree of heterogeneity observed between studies, potentially complicating the interpretation of any meta-analysis.
The results from studies involving a laboratory-confirmed influenza diagnosis suggested that the mean number of working days lost ranged between 1.5 and 4.9 days per episode. Those papers that detailed working days lost per episode following physician diagnosis of influenza reported a range of 3.7–5.9 days per episode. Finally, estimates from papers reporting working days lost per episode of self-reported influenza ranged from <1 day to 4.3 days per episode.
Influenza imposes a significant burden on society, and this review highlights the significant economic impact it causes, i.e. the loss of productivity caused by both absenteeism and by staff functioning at reduced capacity even after they have returned to work. A number of prophylaxis and treatment options exist for influenza and should be given serious consideration in an attempt to reduce the economic burden on society.
Fußnoten
1
A household was recruited when one member (the index case) made an office visit to or received a house call from a physician. A household was included in the study if the following criteria were met: the index case visited a participating physician because of the onset within 48 hours of a fever (temperature >38°C) or feverishness, with respiratory signs, and the index case lived with at least one other person (the contact subject), was the first case in the household, was not hospitalized as a result of this first visit, and consented to virologic sampling and study participation.
 
Literatur
1.
Zurück zum Zitat Couch RB. Influenza: prospects for control. Ann Int Med 2000; 133 (12): 992–8PubMed Couch RB. Influenza: prospects for control. Ann Int Med 2000; 133 (12): 992–8PubMed
2.
Zurück zum Zitat Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian J Immunol 2004; 59 (1): 1–15CrossRef Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian J Immunol 2004; 59 (1): 1–15CrossRef
3.
Zurück zum Zitat Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004; 64 (18): 2031–46PubMedCrossRef Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004; 64 (18): 2031–46PubMedCrossRef
4.
Zurück zum Zitat Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 181–206 Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 181–206
6.
Zurück zum Zitat Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7 (35): 1–170 Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7 (35): 1–170
9.
Zurück zum Zitat Molinari NAM, Ortega-Sanchez IR, Messonnier ML. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086–96PubMedCrossRef Molinari NAM, Ortega-Sanchez IR, Messonnier ML. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086–96PubMedCrossRef
10.
Zurück zum Zitat Lynd LD, Goeree R, O’Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics 2005; 23 (11): 1083–106PubMedCrossRef Lynd LD, Goeree R, O’Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics 2005; 23 (11): 1083–106PubMedCrossRef
11.
Zurück zum Zitat Anonymous. Economic and social impact of epidemic and pandemic influenza. Vaccine 2006; 24 (44–46): 6776–8CrossRef Anonymous. Economic and social impact of epidemic and pandemic influenza. Vaccine 2006; 24 (44–46): 6776–8CrossRef
12.
Zurück zum Zitat Anonymous. Easing the burden: the challenge of managing influenza. Am J Manag Care 2000; 6 (5 Suppl.): S276–81 Anonymous. Easing the burden: the challenge of managing influenza. Am J Manag Care 2000; 6 (5 Suppl.): S276–81
13.
Zurück zum Zitat Sessa A, Lucioni C, D’Ambrosio G, et al. Economic evaluation of clinical influenza in Italy. Int J Med 2005; 7 (1): 14–20 Sessa A, Lucioni C, D’Ambrosio G, et al. Economic evaluation of clinical influenza in Italy. Int J Med 2005; 7 (1): 14–20
14.
15.
Zurück zum Zitat Williams JP, Lednar W. New developments in influenza vaccine technology: a potential new prevention strategy for employers and managed care organizations. AM J Manag Care 2002; 8 (5 Suppl.): S145–56 Williams JP, Lednar W. New developments in influenza vaccine technology: a potential new prevention strategy for employers and managed care organizations. AM J Manag Care 2002; 8 (5 Suppl.): S145–56
16.
Zurück zum Zitat Meier C, Napalkov P, Wegmüller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834–42PubMedCrossRef Meier C, Napalkov P, Wegmüller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834–42PubMedCrossRef
17.
Zurück zum Zitat Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283 (8): 1016–24PubMedCrossRef Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283 (8): 1016–24PubMedCrossRef
18.
Zurück zum Zitat Rhoton-Vlasak A. Viral influenza in women. Primary Care Update Ob Gyns 1999; 6 (1): 1–7CrossRef Rhoton-Vlasak A. Viral influenza in women. Primary Care Update Ob Gyns 1999; 6 (1): 1–7CrossRef
19.
Zurück zum Zitat Anonymous. Evidence points to influenza vaccination being cost-saving in healthy working adults. Drugs Ther Perspect 2003; 19 (3): 22–5CrossRef Anonymous. Evidence points to influenza vaccination being cost-saving in healthy working adults. Drugs Ther Perspect 2003; 19 (3): 22–5CrossRef
20.
Zurück zum Zitat Anonymous. Zanamivir for influenza. Drug Ther Bull 1999; 37 (11): 81–4 Anonymous. Zanamivir for influenza. Drug Ther Bull 1999; 37 (11): 81–4
21.
Zurück zum Zitat Fleming DM. The management of influenza in people of working age. Occup Med 2002; 52 (5): 259–63CrossRef Fleming DM. The management of influenza in people of working age. Occup Med 2002; 52 (5): 259–63CrossRef
22.
Zurück zum Zitat Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 2001; 19 (17–19): 2216–20PubMedCrossRef Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 2001; 19 (17–19): 2216–20PubMedCrossRef
23.
Zurück zum Zitat Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 1998; 10 (199): 1–428 Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 1998; 10 (199): 1–428
24.
Zurück zum Zitat O’Reilly FW, Stevens AB. Sickness absence due to influenza. Occup Med 2002; 52 (5): 265–9CrossRef O’Reilly FW, Stevens AB. Sickness absence due to influenza. Occup Med 2002; 52 (5): 265–9CrossRef
25.
Zurück zum Zitat Smith A. The socioeconomic aspects and behavioural effect of influenza. In: Wood C, editor. Influenza: strategies for prevention. London: Royal Society Medicine, 1988: 46–52 Smith A. The socioeconomic aspects and behavioural effect of influenza. In: Wood C, editor. Influenza: strategies for prevention. London: Royal Society Medicine, 1988: 46–52
26.
Zurück zum Zitat Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1994; 10 (193 Pt 1): 1–260 Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1994; 10 (193 Pt 1): 1–260
27.
Zurück zum Zitat Principi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect Dis 2004; 4 (2): 75–83PubMedCrossRef Principi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect Dis 2004; 4 (2): 75–83PubMedCrossRef
28.
Zurück zum Zitat Teo SS, Nguyen-Van-Tam JS, Booy R. Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps? Arch Dis Child 2005; 90 (5): 532–6PubMedCrossRef Teo SS, Nguyen-Van-Tam JS, Booy R. Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps? Arch Dis Child 2005; 90 (5): 532–6PubMedCrossRef
29.
Zurück zum Zitat Block SL. Role of influenza vaccine for healthy children in the US. Paediatr Drugs 2004; 6 (4): 199–209PubMedCrossRef Block SL. Role of influenza vaccine for healthy children in the US. Paediatr Drugs 2004; 6 (4): 199–209PubMedCrossRef
30.
Zurück zum Zitat Committee on Infectious Diseases. American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2002; 110 (6): 1246–52CrossRef Committee on Infectious Diseases. American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2002; 110 (6): 1246–52CrossRef
31.
Zurück zum Zitat Heikkinen T, Booy R, Campins M, et al. Should healthy children be vaccinated against influenza? Eur J Pediatr 2006; 165 (4): 223–8PubMedCrossRef Heikkinen T, Booy R, Campins M, et al. Should healthy children be vaccinated against influenza? Eur J Pediatr 2006; 165 (4): 223–8PubMedCrossRef
32.
Zurück zum Zitat Jacobson RM, Poland GA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Paediatr Drugs 2002; 4 (1): 65–71PubMed Jacobson RM, Poland GA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Paediatr Drugs 2002; 4 (1): 65–71PubMed
33.
Zurück zum Zitat Gaglani MJ, Herschler GB. Every nose counts: a new influenza vaccine for all healthy schoolchildren? Clin Pediatr 2004; 43 (1): 35–41CrossRef Gaglani MJ, Herschler GB. Every nose counts: a new influenza vaccine for all healthy schoolchildren? Clin Pediatr 2004; 43 (1): 35–41CrossRef
34.
Zurück zum Zitat Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003; 55 (2): 83–91PubMedCrossRef Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003; 55 (2): 83–91PubMedCrossRef
35.
Zurück zum Zitat Szucs TD. Influenza: the role of burden-of-illness research. Pharmacoeconomics 1999; 16 Suppl. 1: 27–32PubMedCrossRef Szucs TD. Influenza: the role of burden-of-illness research. Pharmacoeconomics 1999; 16 Suppl. 1: 27–32PubMedCrossRef
36.
Zurück zum Zitat Nichol KA, Lind A, Margolis K, et al. The effectiveness of vaccination in healthy, working adults. N Engl J Med 1995; 333 (14): 889–93PubMedCrossRef Nichol KA, Lind A, Margolis K, et al. The effectiveness of vaccination in healthy, working adults. N Engl J Med 1995; 333 (14): 889–93PubMedCrossRef
37.
Zurück zum Zitat Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database of Syst Rev 2007; (2): CD001269 Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database of Syst Rev 2007; (2): CD001269
38.
Zurück zum Zitat Ahmed AH, Nicholson KG. The efficacy of influenza vaccine. Rev Med Microbiol 1996; 7 (1): 23–30CrossRef Ahmed AH, Nicholson KG. The efficacy of influenza vaccine. Rev Med Microbiol 1996; 7 (1): 23–30CrossRef
39.
Zurück zum Zitat Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001; 19 (31): 4373–7PubMedCrossRef Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001; 19 (31): 4373–7PubMedCrossRef
40.
Zurück zum Zitat Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21 (17–18): 2207–17PubMedCrossRef Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21 (17–18): 2207–17PubMedCrossRef
41.
Zurück zum Zitat Olsen GW, Steinberg ME, Ley CA. Worksite influenza immunization programs: insight into the implementation and cost-benefit. AAOHN J 2005; 53 (3): 105–10PubMed Olsen GW, Steinberg ME, Ley CA. Worksite influenza immunization programs: insight into the implementation and cost-benefit. AAOHN J 2005; 53 (3): 105–10PubMed
42.
Zurück zum Zitat Szucs TD. Medical economics in the field of influenza: past, present and future. Virus Res 2004; 103 (1–2): 25–30PubMedCrossRef Szucs TD. Medical economics in the field of influenza: past, present and future. Virus Res 2004; 103 (1–2): 25–30PubMedCrossRef
43.
Zurück zum Zitat Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Syst Rev 2006; (2): CD001169 Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Syst Rev 2006; (2): CD001169
44.
Zurück zum Zitat Hayden FG, Atmar RL, Schilling M, et al. and the Oseltamivir Study Group. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43PubMedCrossRef Hayden FG, Atmar RL, Schilling M, et al. and the Oseltamivir Study Group. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43PubMedCrossRef
45.
Zurück zum Zitat Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254–61PubMedCrossRef Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254–61PubMedCrossRef
46.
Zurück zum Zitat Welliver R, Monto AS, Catewicz O, et al. for the Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54PubMedCrossRef Welliver R, Monto AS, Catewicz O, et al. for the Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54PubMedCrossRef
47.
Zurück zum Zitat Hayden FG, Gubareva LV, Monto AS, et al. for the Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282–9PubMedCrossRef Hayden FG, Gubareva LV, Monto AS, et al. for the Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282–9PubMedCrossRef
48.
Zurück zum Zitat Anonymous. Zanamivir and oseltamivirNew options in the management of influenza. Drugs Ther Persp 2000; 15 (6): 1–5CrossRef Anonymous. Zanamivir and oseltamivirNew options in the management of influenza. Drugs Ther Persp 2000; 15 (6): 1–5CrossRef
49.
Zurück zum Zitat McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4 (2): 107–16PubMedCrossRef McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4 (2): 107–16PubMedCrossRef
50.
Zurück zum Zitat Schwarzinger M, Lacombe K, Carrat F. Economic evaluations of neuraminidase inhibitors to control influenza. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3 (2): 147–58CrossRef Schwarzinger M, Lacombe K, Carrat F. Economic evaluations of neuraminidase inhibitors to control influenza. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3 (2): 147–58CrossRef
51.
Zurück zum Zitat Kumpulainen V, Mäkelä M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29 (2): 181–5PubMedCrossRef Kumpulainen V, Mäkelä M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29 (2): 181–5PubMedCrossRef
52.
Zurück zum Zitat Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Int Med 2002; 162 (16): 1842–8CrossRef Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Int Med 2002; 162 (16): 1842–8CrossRef
53.
Zurück zum Zitat Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000; 17 (2): 187–95PubMedCrossRef Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000; 17 (2): 187–95PubMedCrossRef
54.
Zurück zum Zitat Jacomo V, Sartor C, Zandotti C, et al. Nosocomial influenza outbreak in an intensive-care unit. Med Mal Infect 2001; 31 (9): 563–8CrossRef Jacomo V, Sartor C, Zandotti C, et al. Nosocomial influenza outbreak in an intensive-care unit. Med Mal Infect 2001; 31 (9): 563–8CrossRef
55.
Zurück zum Zitat Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002; 23 (10): 615–9PubMedCrossRef Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002; 23 (10): 615–9PubMedCrossRef
56.
Zurück zum Zitat Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test. J Infect Chemother 2006; 12 (2): 70–2PubMedCrossRef Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test. J Infect Chemother 2006; 12 (2): 70–2PubMedCrossRef
57.
Zurück zum Zitat Bosis S, Esposito S, Niesters HGM, et al. Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses. J Med Virol 2005; 75: 101–4PubMedCrossRef Bosis S, Esposito S, Niesters HGM, et al. Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses. J Med Virol 2005; 75: 101–4PubMedCrossRef
58.
Zurück zum Zitat Esposito S, Gasparini R, Bosis S, et al. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005; 11 (11): 933–6PubMedCrossRef Esposito S, Gasparini R, Bosis S, et al. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005; 11 (11): 933–6PubMedCrossRef
59.
Zurück zum Zitat Principi N, Esposito S, Gasparini R, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004; 89 (11): 1002–7PubMedCrossRef Principi N, Esposito S, Gasparini R, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004; 89 (11): 1002–7PubMedCrossRef
60.
Zurück zum Zitat Principi N, Esposito S, Marchisio P, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22 (10 Suppl.): S207–10 Principi N, Esposito S, Marchisio P, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22 (10 Suppl.): S207–10
61.
Zurück zum Zitat Carrat F, Schwarzinger M, Housset B, et al. Antibiotic treatment for influenza does not affect resolution of illness, secondary visits or lost workdays. Eur J Epidemiol 2004; 19 (7): 703–5PubMedCrossRef Carrat F, Schwarzinger M, Housset B, et al. Antibiotic treatment for influenza does not affect resolution of illness, secondary visits or lost workdays. Eur J Epidemiol 2004; 19 (7): 703–5PubMedCrossRef
62.
Zurück zum Zitat Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults cost-effectiveness of rapid testing and antiviral therapy. J Gen Int Med 2003; 18 (10): 808–15CrossRef Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults cost-effectiveness of rapid testing and antiviral therapy. J Gen Int Med 2003; 18 (10): 808–15CrossRef
63.
Zurück zum Zitat Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118 (1): 68–77PubMedCrossRef Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118 (1): 68–77PubMedCrossRef
64.
Zurück zum Zitat Das Gupta R, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with influvac in the UK. Pharmacoeconomics 2002; 20 (7): 475–84PubMedCrossRef Das Gupta R, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with influvac in the UK. Pharmacoeconomics 2002; 20 (7): 475–84PubMedCrossRef
65.
Zurück zum Zitat Millot JL, Aymard M, Bardol A. Reduced efficiency of influenza vaccine in prevention of influenza-like illness in working adults: a 7 month prospective survey in EDF Gaz de France employees, in Rhone-Alpes, 1996–1997. Occup Med 2002; 52 (5): 281–92CrossRef Millot JL, Aymard M, Bardol A. Reduced efficiency of influenza vaccine in prevention of influenza-like illness in working adults: a 7 month prospective survey in EDF Gaz de France employees, in Rhone-Alpes, 1996–1997. Occup Med 2002; 52 (5): 281–92CrossRef
66.
Zurück zum Zitat Sessa A, Costa B, Bamfi F, et al. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001; 18 (6): 629–34PubMedCrossRef Sessa A, Costa B, Bamfi F, et al. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001; 18 (6): 629–34PubMedCrossRef
67.
Zurück zum Zitat Gaillat J, Pecking M, El Sawi A, et al. Neuraminidase inhibitors in the general practice management of influenza: who prescribes them, when and with which results? Med Mal Infect 2005; 35 (9): 435–42PubMedCrossRef Gaillat J, Pecking M, El Sawi A, et al. Neuraminidase inhibitors in the general practice management of influenza: who prescribes them, when and with which results? Med Mal Infect 2005; 35 (9): 435–42PubMedCrossRef
68.
Zurück zum Zitat Lambert S, O’Grady KA, Gabriel S, et al. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell 2004; 28 (4): 510–6 Lambert S, O’Grady KA, Gabriel S, et al. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell 2004; 28 (4): 510–6
69.
Zurück zum Zitat Ng TP, Pwee KH, Niti M, et al. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singap 2002; 31 (2): 182–8PubMed Ng TP, Pwee KH, Niti M, et al. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singap 2002; 31 (2): 182–8PubMed
70.
Zurück zum Zitat Ramadan PA, de Araujo FB, Ferreira Jr M. A 12-month follow-up of an influenza vaccination campaign based on voluntary adherence: report on upper-respiratory symptoms among volunteers and non-volunteers. Rev Paul Med 2001; 119 (4): 142–5 Ramadan PA, de Araujo FB, Ferreira Jr M. A 12-month follow-up of an influenza vaccination campaign based on voluntary adherence: report on upper-respiratory symptoms among volunteers and non-volunteers. Rev Paul Med 2001; 119 (4): 142–5
71.
Zurück zum Zitat Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284 (13): 1655–63PubMedCrossRef Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284 (13): 1655–63PubMedCrossRef
72.
Zurück zum Zitat Dille JH. A worksite influenza immunization program: impact on lost work days, health care utilization, and health care spending. AAOHN J 1999; 47 (7): 301–9PubMed Dille JH. A worksite influenza immunization program: impact on lost work days, health care utilization, and health care spending. AAOHN J 1999; 47 (7): 301–9PubMed
73.
Zurück zum Zitat Mixeu MA, Vespa GN, Forleo-Neto E, et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002; 73 (9): 876–80PubMed Mixeu MA, Vespa GN, Forleo-Neto E, et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002; 73 (9): 876–80PubMed
74.
Zurück zum Zitat King Jr JC, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005; 116 (6): e868–73CrossRef King Jr JC, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005; 116 (6): e868–73CrossRef
75.
Zurück zum Zitat Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18 (9): 779–83PubMedCrossRef Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18 (9): 779–83PubMedCrossRef
76.
Zurück zum Zitat Akazawa M, Sindelar JL, Paltiel AD. Economic costs of influenza-related work absenteeism. Value Health 2003; 6 (2): 107–15PubMedCrossRef Akazawa M, Sindelar JL, Paltiel AD. Economic costs of influenza-related work absenteeism. Value Health 2003; 6 (2): 107–15PubMedCrossRef
77.
Zurück zum Zitat Cohen P, Darling C, Hampson A, et al. Influenza vaccination in an occupational setting: effectiveness and cost-benefit study. J Occup Health Safe Aust NZ 2003; 19 (2): 167–82 Cohen P, Darling C, Hampson A, et al. Influenza vaccination in an occupational setting: effectiveness and cost-benefit study. J Occup Health Safe Aust NZ 2003; 19 (2): 167–82
78.
Zurück zum Zitat Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002; 156 (10): 986–91PubMed Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002; 156 (10): 986–91PubMed
79.
Zurück zum Zitat Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998; 48 (2): 85–90CrossRef Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998; 48 (2): 85–90CrossRef
80.
Zurück zum Zitat Speroni KG, Dawson E, Atherton M, et al. Influenza vaccination: incidence of symptoms and resulting absenteeism in hospital employees. AAOHN J 2005; 53 (11): 477–83PubMed Speroni KG, Dawson E, Atherton M, et al. Influenza vaccination: incidence of symptoms and resulting absenteeism in hospital employees. AAOHN J 2005; 53 (11): 477–83PubMed
81.
Zurück zum Zitat Szucs TD, Ruef C, Muller D, et al. The economic impact of influenza in a university hospital setting. Infect Contr Hosp Epidemiol 2001; 22 (8): 472–4CrossRef Szucs TD, Ruef C, Muller D, et al. The economic impact of influenza in a university hospital setting. Infect Contr Hosp Epidemiol 2001; 22 (8): 472–4CrossRef
82.
Zurück zum Zitat Jefferson T, Wegmuller Y, Barker C, et al. The impact of influenza on the workplace and the effect of the antiviral GS4104 on daily performance and work absenteeism [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 46 Jefferson T, Wegmuller Y, Barker C, et al. The impact of influenza on the workplace and the effect of the antiviral GS4104 on daily performance and work absenteeism [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 46
83.
84.
Zurück zum Zitat Smith AP, Thomas M, Brockman P, et al. Effect of influenza B virus infection on human performance. BMJ 1993; 306: 760–1PubMedCrossRef Smith AP, Thomas M, Brockman P, et al. Effect of influenza B virus infection on human performance. BMJ 1993; 306: 760–1PubMedCrossRef
85.
Zurück zum Zitat Postma MJ, Jansema P, van Genugten ML, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62 (7): 1013–24PubMedCrossRef Postma MJ, Jansema P, van Genugten ML, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62 (7): 1013–24PubMedCrossRef
86.
Zurück zum Zitat Watanabe A, Kobayashi M. Socioeconomic analysis of oseltamivir for influenza patients. Jpn J Chemother 2001; 49 (2): 95–102 Watanabe A, Kobayashi M. Socioeconomic analysis of oseltamivir for influenza patients. Jpn J Chemother 2001; 49 (2): 95–102
87.
Zurück zum Zitat Prosser LA, O’Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmaceoeconomics 2008; 26 (2): 163–78CrossRef Prosser LA, O’Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmaceoeconomics 2008; 26 (2): 163–78CrossRef
Metadaten
Titel
The Impact of Influenza on Working Days Lost
A Review of the Literature
verfasst von
Dr Martin Keech
Paul Beardsworth
Publikationsdatum
01.11.2008
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 11/2008
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200826110-00004

Weitere Artikel der Ausgabe 11/2008

PharmacoEconomics 11/2008 Zur Ausgabe